Item request has been placed!
×
Item request cannot be made.
×
Processing Request
EpiPenalty vs. EpiPenance.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Dana Barlow, Rick
- Source:
Healthcare Purchasing News. Oct2016, Vol. 40 Issue 10, preceding p6-6. 2/3p.
- Subject Terms:
- Additional Information
- Abstract:
The author explores controversies associated with the pricing strategy of Mylan Pharmaceuticals for its EpiPen epinephrine autoinjector product. Topics discussed include the negative publicity earned by Mylan and its chief executive officer (CEO), Heather Bresch, the introduction of a generic alternative to EpiPen by Mylan, and the regulation of drug pricing by the U.S. federal government.
No Comments.